Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01158534 · ClinicalTrials.gov registry record · Phase 2
Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery
A Phase 2 study of Renal Cell Cancer and Stage IV Renal Cell Cancer, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT01158534 is a Phase 2 study of Renal Cell Cancer and Stage IV Renal Cell Cancer that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 17 participants, below the 125-participant average among 10 other Renal Cell Cancer trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01158534, a Phase 2 study of Renal Cell Cancer and Stage IV Renal Cell Cancer, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Recombinant interferon alfa-2b may interfere with the growth of cancer cells and slow the growth of kidney cancer. Giving celecoxib together with recombinant interferon alpha-2b may kill more tumor cells and be an effective treatment for metastatic kidney cancer. PURPOSE: This phase II trial is studying how well giving celecoxib together with recombinant interferon alfa-2b works in treating patients with metastatic kidney cancer who have undergone surgery.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG celecoxib
- BIOLOGICAL recombinant interferon alfa-2b
- OTHER polymerase chain reaction
- OTHER reverse transcriptase-polymerase chain reaction
Study Locations (1)
Ohio
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2006-03 |
| Est. Completion | 2010-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01158534
The ClinicalTrials.gov registry entry for NCT01158534 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 125-participant average among 10 other Renal Cell Cancer trials with a reported enrollment target (86% lower). The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Renal Cell Cancer appearing as the primary indexed condition, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT01158534 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT01158534 about?
NCT01158534 is a clinical study titled "Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery". RATIONALE: Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Recombinant interferon alfa-2b may interfere with the growth of cancer cells and slow the growth of kidney cancer. Giving celecoxib together with recombinant interferon alpha-2b may kill m...
What is the current status of trial NCT01158534?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2006-03. Estimated completion is 2010-10.
What conditions does trial NCT01158534 study?
This clinical trial studies the following conditions: Renal Cell Cancer, Stage IV Renal Cell Cancer.
What interventions are being tested in trial NCT01158534?
The interventions under investigation include: laboratory biomarker analysis (OTHER), celecoxib (DRUG), recombinant interferon alfa-2b (BIOLOGICAL), polymerase chain reaction (OTHER), reverse transcriptase-polymerase chain reaction (OTHER).
Who is sponsoring clinical trial NCT01158534?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01158534 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors
ACTIVE NOT RECRUITING · Phase 2
-
Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity
COMPLETED · Phase 2
-
Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer
COMPLETED · Phase 2
-
TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors
RECRUITING · Phase 1
-
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.